


ARV-393

Cat. No.:	HY-158105
CAS No.:	2851885-95-3
Molecular Formula:	C ₄₆ H ₅₃ ClFN ₉ O ₇
Molecular Weight:	898.42
Target:	PROTACs; BCL6
Pathway:	PROTAC; Immunology/Inflammation
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 11.67 mg/mL (12.99 mM; ultrasonic and warming and heat to 60°C)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.1131 mL	5.5653 mL	11.1307 mL
	5 mM	0.2226 mL	1.1131 mL	2.2261 mL
	10 mM	0.1113 mL	0.5565 mL	1.1131 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

ARV-393 is an orally active PROTAC that utilizes the ubiquitin-proteasome system to target the degradation of BCL6. ARV-393 consists of ligand conjugates targeting BCL6 and the E3 ligase cereblon, respectively. ARV-393 has DC₅₀ and GI₅₀ values of <1 nM in multiple cell lines of diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). ARV-393 also demonstrated considerable tumor suppressor activity in tumor xenograft models. ARV-393 is being studied to inhibit non-Hodgkin lymphoma.

IC₅₀ & Target

BCL6^[1]

REFERENCES

[1]. Sherman D. Abstract ND05: The discovery of ARV-393, a potent, orally bioavailable BCL6 targeting PROTAC[®] for the treatment of Non-Hodgkin's Lymphoma[J]. Cancer Research, 2024, 84(7_Supplement): ND05-ND05.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA